Worthwhile: an article, a presentation, and a ... - CLL Support

CLL Support

23,088 members39,645 posts

Worthwhile: an article, a presentation, and a table

Luap001 profile image
1 Reply

The article focuses on NOTCH1 (and also -2 and -4 as these are involved in CLL) both mutated and activated forms as applicable. I refer to these collectively as NOTCH.

The article includes among other things how NOTCH can point to limited effectiveness of ibrutinib (once you start treatment), on how a mutation may mean non-responsiveness to chemo for patients who are fit, under age 65, and umIGHV, involvement of NOTCH with Richter’s transformation, also involvement with squamous cell carcinoma, and with how it can identify an end around BCL2 (limiting the effectiveness of Venetoclax) by pointing to the presence of an alternative path to preventing apoptosis. The author even poses a good question not necessarily related to NOTCH: If you have low CD20 expression, do you really want to use an anti-CD20 antibody given its contribution to treatment toxicity. I guess if you are offered a CD20 antibody, a good question to ask is how much CD20 expression do you have.

The presentation talks about identifying resistance to Venetoclax.

The table quantifies the risk of factors associated with the development of secondary cancers in CLL.

cllsociety.org/2018/06/cll-...

duckduckgo.com/?q=notch+the...

ncbi.nlm.nih.gov/pmc/articl...

Written by
Luap001 profile image
Luap001
To view profiles and participate in discussions please or .
Read more about...
1 Reply
BethIlia profile image
BethIlia

Thank you.

Not what you're looking for?

You may also like...

Role of RITUXIMAB in CLL treatment in combination with Venetoclax

Hello to all fellows in the CLL journey! Has anyone found a clear answer as to what exactly is the...

Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis

Given the interest in my recent response to @[571533] about whether our immune system will get...

Encouraging results from venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

We've heard that re-treatment with venetoclax is possible. Per the attached image, here's some...

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

From the New England Journal of Medicine 10th December 2023 "The CLL treatment landscape has...

Triplet Regimen Shows Promise in CLL -Zanubrutinib, obinutuzumab, & venetoclax combo achieves rapid undetectable MRD -MedPageToday -07/07/20

Treatment triple-header news from the MedPage Today. From the article: At the American Society...